BioCentury | Dec 30, 2016
Emerging Company Profile

Mining for substitutions

Riptide Bioscience Inc. has mined the sequences and structures of failed first-generation peptide therapeutics to engineer a new class of host defense peptides with amino acid substitutions that could make its candidates more effective in...
BioCentury | Apr 2, 2015
Distillery Therapeutics

Therapeutics: Factor XIIa; β-amyloid 42 (Aβ42)

Neurology INDICATION: Alzheimer's disease (AD) Studies in patient samples and mice suggest systemic Factor XIIa inhibition could help treat AD. In serum from AD patients, levels of Factor XIIa and markers of kallikrein - which cleaves...
BioCentury | Feb 27, 2014
Targets & Mechanisms

The XII factor

Factor XII sits atop one branch of the clotting cascade but has not been pursued for treating and preventing thrombosis because it was seen as a minor player in blood coagulation. Now, a group from...
BioCentury | Dec 24, 2012
Clinical News

DPK-060: Phase II data

Top-line data from a double-blind, placebo-controlled, Swedish Phase II trial in 69 patients with acute external otitis caused by bacterial or fungal pathogens showed that thrice-daily DPK-060 2% ear drops for 7-10 days was safe...
BioCentury | Oct 17, 2011
Emerging Company Profile

KalVista: Filling the VEGF void

KalVista Pharmaceuticals Ltd. believes its small molecule plasma kallikrein inhibitors will treat diabetic macular edema on par with VEGF inhibitors and will work in more patients. The biotech also hopes to offer injectable and oral...
BioCentury | Jun 4, 2009
Distillery Therapeutics

Indication: Infectious disease

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Sepsis; streptococcus infection Kininogen-1 (KNG-1...
...In vitro and mouse studies suggest that a peptide mimic of the bacteria-binding region of KNG-1...
BioCentury | Jan 29, 2009
Distillery Therapeutics

Indication: Various

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Cancer; diabetic retinopathy Ferritin, heavy polypeptide 1 (FTH1); cleaved high molecular weight kininogen (HKa) Studies in cell culture and in mice...
BioCentury | Nov 1, 2004
Product Development

Treating HAE

Treating HAE In normal patients, C1 esterase inhibitor can normalize inflammation by intervening to slow formation of prekallikrien from Factor XIIa or by inhibiting conversion of HMW-kininogen. Kallikrein mediates the release of bradykinin from precursors....
BioCentury | Sep 3, 2002
Company News

Attenuon other research news

Researchers published in the Proceedings of the National Academy of Sciences evidence for the use of HKa as an anti-angiogenic compound. In culture, HKa induced endothelial cell apoptosis and inhibited angiogenesis in the chick chorioallantoic...
Items per page:
1 - 9 of 9